Jump to main content
Jump to site search

Issue 12, 2011
Previous Article Next Article

A new platinum-complex showing easy preparation, promising anti-tumor activity, and better efficacy and distribution properties than oxaliplatin

Author affiliations

Abstract

Current clinically used chemotherapeutic platinum drugs can trigger severe toxic effects. To develop a model system for the evaluation of the therapeutic efficacy and the toxic effects of new platinum agents, we have synthesized a new compound N-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxylhex-1-yl]-L-hydroxyproline dichloroplatinum(II) (PHDP), compared its in vitro anti-proliferation activity, in vivo anti-tumor activity and safety to those of oxaliplatin, and correlated all these biological actions with the platinum occurring in the spleen, kidney, heart, brain, blood, tumor tissue, urine and faeces of the treated mice. We explored the atomic absorption based determinations of the platinum which occurred in the spleen, kidney, heart, brain, blood, tumor tissue, urine and faeces and constitute a model system that can be generally used in the investigation of the novel platinum agents.

Graphical abstract: A new platinum-complex showing easy preparation, promising anti-tumor activity, and better efficacy and distribution properties than oxaliplatin

Back to tab navigation

Article information


Submitted
27 Jun 2011
Accepted
05 Sep 2011
First published
18 Oct 2011

Mol. BioSyst., 2011,7, 3245-3252
Article type
Paper

A new platinum-complex showing easy preparation, promising anti-tumor activity, and better efficacy and distribution properties than oxaliplatin

Y. Wang, G. Kang, M. Zhao, J. Wu, X. Zhang, Y. Yang, J. Liu and S. Peng, Mol. BioSyst., 2011, 7, 3245
DOI: 10.1039/C1MB05266G

Search articles by author

Spotlight

Advertisements